Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.495 -0.095 (-5.97%)
Streaming Delayed Price Updated: 11:10 AM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗
INmune Bio (INMB) reported a narrower-than-expected Q3 2025 loss, sparking a positive after-hours market reaction for the clinical-stage biotech firm. 
Via Chartmill
News headline image
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio (INMB) Q2 Loss Widens 110% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗
Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday. 
Via Benzinga
News headline image
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday ↗
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. 
Via Benzinga
News headline image
Which stocks have an unusual volume on Thursday? ↗
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
News headline image
This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Crude Oil Moves Lower; Joby Aviation Shares Surge ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain ↗
INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.